162 related articles for article (PubMed ID: 37816957)
1. Population Pharmacokinetics of Digoxin in Nonagenarian Patients: Optimization of the Dosing Regimen.
Salcedo-Mingoarranz AL; Medellín-Garibay SE; Barcia-Hernández E; García-Díaz B
Clin Pharmacokinet; 2023 Dec; 62(12):1725-1738. PubMed ID: 37816957
[TBL] [Abstract][Full Text] [Related]
2. A population pharmacokinetic analysis of the influence of nutritional status of digoxin in hospitalized Korean patients.
Choi SA; Yun HY; Lee ES; Shin WG
Clin Ther; 2014 Mar; 36(3):389-400. PubMed ID: 24612944
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of digoxin in Thai pediatric patients.
Preechagoon Y; Somsaard P; Petcharattana S
J Med Assoc Thai; 2009 Oct; 92(10):1324-35. PubMed ID: 19845241
[TBL] [Abstract][Full Text] [Related]
4. Determination of digoxin clearance in Japanese elderly patients for optimization of drug therapy: a population pharmacokinetics analysis using nonlinear mixed-effects modelling.
Yukawa M; Yukawa E; Suematsu F; Takiguchi T; Ikeda H; Aki H; Mimemoto M
Drugs Aging; 2011 Oct; 28(10):831-41. PubMed ID: 21970310
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of digoxin in Korean patients.
Nagaraja NV; Park YJ; Jeon S; Sands CD; Derendorf H
Int J Clin Pharmacol Ther; 2000 Jun; 38(6):291-7. PubMed ID: 10890577
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic analysis of digoxin in Chinese neonates and infants.
Gong Y; Chen Y; Li Q; Li Z
J Pharmacol Sci; 2014; 125(2):142-9. PubMed ID: 24837877
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetic Analysis of Dorzagliatin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus.
Wang K; Feng L; Zhang J; Zou Q; Xu F; Sun Z; Tang F; Chen L
Clin Pharmacokinet; 2023 Oct; 62(10):1413-1425. PubMed ID: 37537410
[TBL] [Abstract][Full Text] [Related]
8. Impact of SLCO4C1 Genotypes, Creatinine, and Spironolactone on Digoxin Population Pharmacokinetic Variables in Patients With Cardiac Insufficiency.
Du P; Wang A; Ma Y; Jia A; Li Y; Li X
Clin Ther; 2020 Sep; 42(9):1799-1810.e3. PubMed ID: 32798059
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of vancomycin and dosing recommendations for trauma patients.
Medellín-Garibay SE; Ortiz-Martín B; Rueda-Naharro A; García B; Romano-Moreno S; Barcia E
J Antimicrob Chemother; 2016 Feb; 71(2):471-9. PubMed ID: 26568565
[TBL] [Abstract][Full Text] [Related]
10. Utility of cystatin C and serum creatinine-based glomerular filtration rate equations in predicting vancomycin clearance: A population pharmacokinetics analysis in elderly Chinese patients.
Ling J; Yang X; Dong L; Jiang Y; Zou S; Hu N
Biopharm Drug Dispos; 2024 Feb; 45(1):58-68. PubMed ID: 38319316
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.
Mittapalli RK; Nuthalapati S; Shepherd SP; Xiong H
Cancer Chemother Pharmacol; 2017 Mar; 79(3):587-594. PubMed ID: 28247011
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic model of digoxin in older Chinese patients and its application in clinical practice.
Zhou XD; Gao Y; Guan Z; Li ZD; Li J
Acta Pharmacol Sin; 2010 Jun; 31(6):753-8. PubMed ID: 20523346
[TBL] [Abstract][Full Text] [Related]
13. Application of two-point assay of digoxin serum concentration in studying population pharmacokinetics in Egyptian pediatric patients with heart failure: does it make sense?
el-Desoky ES; Madabushi R; Amry Sel-D; Bhattaram VA; Derendorf H
Am J Ther; 2005; 12(4):320-7. PubMed ID: 16041195
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of digoxin in pediatric patients.
Martín-Suárez A; Falcao AC; Outeda M; Hernández FJ; González MC; Quero M; Arranz I; Lanao JM
Ther Drug Monit; 2002 Dec; 24(6):742-5. PubMed ID: 12451291
[TBL] [Abstract][Full Text] [Related]
15. Digoxin population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens.
Yukawa E; Mine H; Higuchi S; Aoyama T
J Pharm Pharmacol; 1992 Sep; 44(9):761-5. PubMed ID: 1360530
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics and dosing optimization of olanzapine in Chinese paediatric patients: Based on the impact of sex and concomitant valproate on clearance.
Xiao T; Hu JQ; Liu SJ; Lu HQ; Li XL; Kong W; Huang SQ; Zhu XQ; Zhang M; Lu HY; Ni XJ; Yang HL; Shang DW; Wen YG
J Clin Pharm Ther; 2022 Nov; 47(11):1811-1819. PubMed ID: 36101489
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model.
Yukawa E; Suematu F; Yukawa M; Minemoto M; Ohdo S; Higuchi S; Goto Y; Aoyama T
Clin Pharmacokinet; 2001; 40(10):773-81. PubMed ID: 11707062
[TBL] [Abstract][Full Text] [Related]
18. A population pharmacokinetic model of ciclosporin applicable for assisting dose management of kidney transplant recipients.
Falck P; Midtvedt K; Vân Lê TT; Storehagen L; Holdaas H; Hartmann A; Asberg A
Clin Pharmacokinet; 2009; 48(9):615-23. PubMed ID: 19725595
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of gentamicin and dosing optimization for infants.
Medellín-Garibay SE; Rueda-Naharro A; Peña-Cabia S; García B; Romano-Moreno S; Barcia E
Antimicrob Agents Chemother; 2015 Jan; 59(1):482-9. PubMed ID: 25385111
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic investigation of digoxin in Japanese infants and young children.
Yukawa M; Yukawa E; Suematsu F; Takiguchi T; Ikeda H; Aki H; Mimemoto M
J Clin Pharmacol; 2011 Jun; 51(6):857-63. PubMed ID: 20592416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
